Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especia...
Main Authors: | Gary D Steinberg, Neal Shore, Petros Grivas, Matthew D Galsky, Elizabeth R Plimack, Shilpa Gupta, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Jonathan E Rosenberg, Ashish M Kamat |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002552.full |
Similar Items
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
by: Ronald Levy, et al.
Published: (2020-07-01) -
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
by: Michael M Boyiadzis, et al.
Published: (2020-07-01) -
Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
by: Gavin Thurston, et al.
Published: (2021-01-01) -
Role of immunotherapy in localized muscle invasive urothelial cancer
by: Jasmeet Kaur, et al.
Published: (2021-09-01) -
Correction: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the society for immunotherapy of cancer (SITC) 2019 Quality Summit
by: Christopher R Heery, et al.
Published: (2020-06-01)